A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation

A. Rostami-Hodjegan, M.R. Shiran, G.T. Tucker, Barbara R. Conway, William J. Irwin, Lance R. Shaw, Tim J. Grattan

Research output: Contribution to journalArticle

Abstract

The objective of this study was to compare the in vitro dissolution profile of a new rapidly absorbed paracetamol tablet containing sodium bicarbonate (PS) with that of a conventional paracetamol tablet (P), and to relate these by deconvolution and mapping to in vivo release. The dissolution methods used include the standard procedure described in the USP monograph for paracetamol tablets, employing buffer at pH5.8 or 0.05 M HCl at stirrer speeds between 10 and 50 rpm. The mapping process was developed and implemented in Microsoft Excel® worksheets that iteratively calculated the optimal values of scale and shape factors which linked in vivo time to in vitro time. The in vitro-in vivo correlation (IVIVC) was carried out simultaneously for both formulations to produce common mapping factors. The USP method, using buffer at pH5.8, demonstrated no difference between the two products. However, using an acidic medium the rate of dissolution of P but not of PS decreased with decreasing stirrer speed. A significant correlation (r=0.773; p<.00001) was established between in vivo release and in vitro dissolution using the profiles obtained with 0.05 M HCl and a stirrer speed of 30 rpm. The scale factor for optimal simultaneous IVIVC in the fasting state was 2.54 and the shape factor was 0.16; corresponding values for mapping in the fed state were 3.37 and 0.13 (implying a larger in vitro-in vivo time difference but reduced shape difference in the fed state). The current IVIVC explains, in part, the observed in vivo variability of the two products. The approach to mapping may also be extended to different batches of these products, to predict the impact of any changes of in vitro dissolution on in vivo release and plasma drug concentration-time profiles.

Original languageEnglish
Pages (from-to)533-543
Number of pages11
JournalDrug Development and Industrial Pharmacy
Volume28
Issue number5
DOIs
Publication statusPublished - 4 Jul 2002

Fingerprint

Sodium Bicarbonate
Acetaminophen
Tablets
Dissolution
Buffers
Deconvolution
In Vitro Techniques
Plasmas
Fasting
Pharmaceutical Preparations

Keywords

  • deconvolution
  • dissolution test
  • in vitro-in vivo correlation
  • paracetamol

Cite this

Rostami-Hodjegan, A., Shiran, M. R., Tucker, G. T., Conway, B. R., Irwin, W. J., Shaw, L. R., & Grattan, T. J. (2002). A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. Drug Development and Industrial Pharmacy, 28(5), 533-543. https://doi.org/10.1081/DDC-120003449
Rostami-Hodjegan, A. ; Shiran, M.R. ; Tucker, G.T. ; Conway, Barbara R. ; Irwin, William J. ; Shaw, Lance R. ; Grattan, Tim J. / A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. In: Drug Development and Industrial Pharmacy. 2002 ; Vol. 28, No. 5. pp. 533-543.
@article{1dfe38a180ed448295a20d35b38cc84b,
title = "A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation",
abstract = "The objective of this study was to compare the in vitro dissolution profile of a new rapidly absorbed paracetamol tablet containing sodium bicarbonate (PS) with that of a conventional paracetamol tablet (P), and to relate these by deconvolution and mapping to in vivo release. The dissolution methods used include the standard procedure described in the USP monograph for paracetamol tablets, employing buffer at pH5.8 or 0.05 M HCl at stirrer speeds between 10 and 50 rpm. The mapping process was developed and implemented in Microsoft Excel{\circledR} worksheets that iteratively calculated the optimal values of scale and shape factors which linked in vivo time to in vitro time. The in vitro-in vivo correlation (IVIVC) was carried out simultaneously for both formulations to produce common mapping factors. The USP method, using buffer at pH5.8, demonstrated no difference between the two products. However, using an acidic medium the rate of dissolution of P but not of PS decreased with decreasing stirrer speed. A significant correlation (r=0.773; p<.00001) was established between in vivo release and in vitro dissolution using the profiles obtained with 0.05 M HCl and a stirrer speed of 30 rpm. The scale factor for optimal simultaneous IVIVC in the fasting state was 2.54 and the shape factor was 0.16; corresponding values for mapping in the fed state were 3.37 and 0.13 (implying a larger in vitro-in vivo time difference but reduced shape difference in the fed state). The current IVIVC explains, in part, the observed in vivo variability of the two products. The approach to mapping may also be extended to different batches of these products, to predict the impact of any changes of in vitro dissolution on in vivo release and plasma drug concentration-time profiles.",
keywords = "deconvolution, dissolution test, in vitro-in vivo correlation, paracetamol",
author = "A. Rostami-Hodjegan and M.R. Shiran and G.T. Tucker and Conway, {Barbara R.} and Irwin, {William J.} and Shaw, {Lance R.} and Grattan, {Tim J.}",
year = "2002",
month = "7",
day = "4",
doi = "10.1081/DDC-120003449",
language = "English",
volume = "28",
pages = "533--543",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
publisher = "Informa Healthcare",
number = "5",

}

A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. / Rostami-Hodjegan, A.; Shiran, M.R.; Tucker, G.T.; Conway, Barbara R.; Irwin, William J.; Shaw, Lance R.; Grattan, Tim J.

In: Drug Development and Industrial Pharmacy, Vol. 28, No. 5, 04.07.2002, p. 533-543.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation

AU - Rostami-Hodjegan, A.

AU - Shiran, M.R.

AU - Tucker, G.T.

AU - Conway, Barbara R.

AU - Irwin, William J.

AU - Shaw, Lance R.

AU - Grattan, Tim J.

PY - 2002/7/4

Y1 - 2002/7/4

N2 - The objective of this study was to compare the in vitro dissolution profile of a new rapidly absorbed paracetamol tablet containing sodium bicarbonate (PS) with that of a conventional paracetamol tablet (P), and to relate these by deconvolution and mapping to in vivo release. The dissolution methods used include the standard procedure described in the USP monograph for paracetamol tablets, employing buffer at pH5.8 or 0.05 M HCl at stirrer speeds between 10 and 50 rpm. The mapping process was developed and implemented in Microsoft Excel® worksheets that iteratively calculated the optimal values of scale and shape factors which linked in vivo time to in vitro time. The in vitro-in vivo correlation (IVIVC) was carried out simultaneously for both formulations to produce common mapping factors. The USP method, using buffer at pH5.8, demonstrated no difference between the two products. However, using an acidic medium the rate of dissolution of P but not of PS decreased with decreasing stirrer speed. A significant correlation (r=0.773; p<.00001) was established between in vivo release and in vitro dissolution using the profiles obtained with 0.05 M HCl and a stirrer speed of 30 rpm. The scale factor for optimal simultaneous IVIVC in the fasting state was 2.54 and the shape factor was 0.16; corresponding values for mapping in the fed state were 3.37 and 0.13 (implying a larger in vitro-in vivo time difference but reduced shape difference in the fed state). The current IVIVC explains, in part, the observed in vivo variability of the two products. The approach to mapping may also be extended to different batches of these products, to predict the impact of any changes of in vitro dissolution on in vivo release and plasma drug concentration-time profiles.

AB - The objective of this study was to compare the in vitro dissolution profile of a new rapidly absorbed paracetamol tablet containing sodium bicarbonate (PS) with that of a conventional paracetamol tablet (P), and to relate these by deconvolution and mapping to in vivo release. The dissolution methods used include the standard procedure described in the USP monograph for paracetamol tablets, employing buffer at pH5.8 or 0.05 M HCl at stirrer speeds between 10 and 50 rpm. The mapping process was developed and implemented in Microsoft Excel® worksheets that iteratively calculated the optimal values of scale and shape factors which linked in vivo time to in vitro time. The in vitro-in vivo correlation (IVIVC) was carried out simultaneously for both formulations to produce common mapping factors. The USP method, using buffer at pH5.8, demonstrated no difference between the two products. However, using an acidic medium the rate of dissolution of P but not of PS decreased with decreasing stirrer speed. A significant correlation (r=0.773; p<.00001) was established between in vivo release and in vitro dissolution using the profiles obtained with 0.05 M HCl and a stirrer speed of 30 rpm. The scale factor for optimal simultaneous IVIVC in the fasting state was 2.54 and the shape factor was 0.16; corresponding values for mapping in the fed state were 3.37 and 0.13 (implying a larger in vitro-in vivo time difference but reduced shape difference in the fed state). The current IVIVC explains, in part, the observed in vivo variability of the two products. The approach to mapping may also be extended to different batches of these products, to predict the impact of any changes of in vitro dissolution on in vivo release and plasma drug concentration-time profiles.

KW - deconvolution

KW - dissolution test

KW - in vitro-in vivo correlation

KW - paracetamol

UR - http://www.scopus.com/inward/record.url?scp=0035999084&partnerID=8YFLogxK

U2 - 10.1081/DDC-120003449

DO - 10.1081/DDC-120003449

M3 - Article

C2 - 12098842

VL - 28

SP - 533

EP - 543

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

IS - 5

ER -